MeiraGTx Holdings plc - Ordinary Shares (NQ:MGTX)

10.79 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about MeiraGTx Holdings plc - Ordinary Shares

< Previous 1 2 3 4 Next >

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

March 13, 2025

Via Benzinga

There are notable gap-ups and gap-downs in today's session. ↗

March 13, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps.

Via Chartmill

Crude Oil Falls 1%; Dollar General Posts Upbeat Sales ↗

March 13, 2025

Via Benzinga

G-III Apparel Posts Better-Than-Expected Earnings, Joins Ballard Power Systems, Dollar General And Other Big Stocks Moving Higher On Thursday ↗

March 13, 2025

Via Benzinga

Recap: MeiraGTx Hldgs Q4 Earnings ↗

March 14, 2024

Via Benzinga

MeiraGTx Collaborates With Hologen AI To Expedite Development Of Parkinson's Candidate, Stock Soars ↗

March 13, 2025

MeiraGTx and Hologen form a neuro-AI drug development joint venture, with up to $430M in funding to advance Parkinson's and CNS treatments.

Via Benzinga

Topics Artificial Intelligence

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

March 13, 2025

Via Benzinga

MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

March 13, 2025

From MeiraGTx

Via GlobeNewswire

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process

March 13, 2025

From MeiraGTx

Via GlobeNewswire

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

February 21, 2025

From MeiraGTx

Via GlobeNewswire

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

January 22, 2025

MeiraGTx has recently received Rare Pediatric Disease Designation (RPDD) for four inherited retinal diseases (IRDs) reflecting the transformative therapeutic potential of the Company’s proprietary...

From MeiraGTx

Via GlobeNewswire

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

December 09, 2024

From MeiraGTx

Via GlobeNewswire

MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates

November 13, 2024

From MeiraGTx

Via GlobeNewswire

Jim Cramer: This Tech Stock Is A Buy, SoFi Technologies Is Good ↗

November 08, 2024

SoFi Technologies, Inc. is good, Jim Cramer said. It reported third-quarter adjusted sales of $689.445 million, according to Benzinga Pro.

Via Benzinga

MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress

October 22, 2024

Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy Platforms

From MeiraGTx

Via GlobeNewswire

Nasdaq Down 150 Points; Johnson & Johnson Reports Better-Than-Expected Q3 Results ↗

October 15, 2024

Via Benzinga

Small Cap-MeiraGTx Reveals Encouraging Data From Parkinson's Study Showing Significant, Clinically Meaningful Changes in Key Efficacy Endpoints ↗

October 15, 2024

MeiraGTx's clinical study of AAV-GAD for Parkinson's disease showed significant improvements in motor function and quality of life in high- and low-dose groups, with no serious adverse events....

Via Benzinga

Crude Oil Tumbles 5%; Goldman Sachs Earnings Top Views ↗

October 15, 2024

Via Benzinga

Walgreens Posts Upbeat Earnings, Joins Wolfspeed, Ericsson And Other Big Stocks Moving Higher On Tuesday ↗

October 15, 2024

Via Benzinga

MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease

October 15, 2024

From MeiraGTx

Via GlobeNewswire

MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference

October 09, 2024

Results indicate a potent and effective locally delivered AAV-BDNF gene therapy for the treatment of obesity caused by MC4R deficiency

From MeiraGTx

Via GlobeNewswire

MGTX Stock Earnings: MeiraGTx Hldgs Misses EPS, Misses Revenue for Q2 2024 ↗

August 12, 2024

MGTX stock results show that MeiraGTx Hldgs missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Via InvestorPlace

MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results

August 12, 2024

From MeiraGTx

Via GlobeNewswire

MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi

August 12, 2024

From MeiraGTx

Via GlobeNewswire

Jim Cramer Calls This Healthcare Stock A 'Worthy Spec,' Recommends Avoiding Canada Goose ↗

May 21, 2024

Cramer recommends staying away from Canada Goose, even though it reported better-than-expected Q4 earnings.

Via Benzinga

MGTX Stock Earnings: MeiraGTx Hldgs Beats EPS, Misses Revenue for Q1 2024 ↗

May 09, 2024

MGTX stock results show that MeiraGTx Hldgs beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

MeiraGTx Reports First Quarter 2024 Financial and Operational Results

May 09, 2024

From MeiraGTx

Via GlobeNewswire

MeiraGTx to Participate in Upcoming Investor Conferences

April 24, 2024

From MeiraGTx

Via GlobeNewswire

MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference

April 18, 2024

From MeiraGTx

Via GlobeNewswire

MGTX Stock Earnings: MeiraGTx Hldgs Beats EPS, Misses Revenue for Q4 2023 ↗

March 14, 2024

MGTX stock results show that MeiraGTx Hldgs beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.

Via InvestorPlace

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.